{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Troglitazone",
  "nciThesaurus": {
    "casRegistry": "97322-87-7",
    "chebiId": "CHEBI:9753",
    "chemicalFormula": "",
    "definition": "An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity.  Troglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis.  This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.",
    "fdaUniiCode": "I66ZZ0ZN0E",
    "identifier": "C1522",
    "preferredName": "Troglitazone",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1934",
      "C98241"
    ],
    "synonyms": [
      "5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-2,4-Thiazolidinedione",
      "5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione",
      "CI-991",
      "CS-045",
      "Prelay",
      "Rezulin",
      "Romozin",
      "TROGLITAZONE",
      "Troglitazone"
    ]
  }
}